Abstract
BackgroundBladder cancer (BCa) is a frequent urothelial malignancy with a high ratio of morbidity and mortality. Various genetic and environmental factors are involved in BCa progression. Since, majority of BCa cases are diagnosed after macroscopic clinical symptoms, it is required to find efficient markers for the early detection. Receptor tyrosine-kinases (RTKs) and non-receptor tyrosine-kinases (nRTKs) have pivotal roles in various cellular processes such as growth, migration, differentiation, and metabolism through different signaling pathways. Tyrosine-kinase deregulations are observed during tumor progressions via mutations, amplification, and chromosomal abnormalities which introduces these factors as important candidates of anti-cancer therapies.Main bodyFor the first time in present review we have summarized all of the reported tyrosine-kinases which have been significantly associated with the clinicopathological features of BCa patients.ConclusionsThis review highlights the importance of tyrosine-kinases as critical markers in early detection and therapeutic purposes among BCa patients and clarifies the molecular biology of tyrosine-kinases during BCa progression and metastasis.Ea-QJd6d7Vebf_yakxqnzFVideo abstract
Highlights
Receptor tyrosine-kinases (RTKs) class I The ERBB family includes ERBB1 (EGFR), ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4) that are the class I receptors of tyrosine-kinases (RTKs)
Tyrosinekinases have essential roles in Bladder cancer (BCa) progression, in present review we have summarized all of the studies which have been assessed the role of tyrosine-kinases in BCa patients in the world (Table 1)
It has been observed that the HER2 amplification was significantly increased in urothelial bladder tumors with lymph node metastasis compared with initial tumors
Summary
It was observed that the class I and V of RTKs were the most reported tyrosine-kinases among BCa patients in the world.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
